Priced Sep 17, 2026 · range was $14–$16 · latest SEC filing Nov 16, 2026.
Pinch-zoom for details.
Not yet summarized; the SEC classifies it as: Biological Products, (No Diagnostic Substances). See the filing for its business.
Fiscal year
1st half
Fiscal year
1st half
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (26.3M) | (61.9M) | −135% | (25.4M) | (50.2M) | −98.0% |
| Net result | (24.8M) | (62.0M) | −150% | (25.4M) | (48.9M) | −92.9% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (26.3M) | (61.9M) | −135% |
| Net result | (24.8M) | (62.0M) | −150% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (25.4M) | (50.2M) | −98.0% |
| Net result | (25.4M) | (48.9M) | −92.9% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing doesn't set out its risks in a list we could read.
The filing doesn't set out its strategy in a list we could read.
Source: Electra Therapeutics, Inc.'s Form 424B4, filed with the SEC on Sep 18, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back